



## Complete Summary

---

### GUIDELINE TITLE

United Kingdom national guideline on the management of molluscum contagiosum.

### BIBLIOGRAPHIC SOURCE(S)

Clinical Effectiveness Group, British Association for Sexual Health and HIV (BASHH). United Kingdom national guideline on the management of molluscum contagiosum. London (UK): British Association for Sexual Health and HIV (BASHH); 2008 Feb 15. 5 p. [11 references]

### GUIDELINE STATUS

This is the current release of the guideline.

This guideline updates a previous version: Association for Genitourinary Medicine (AGUM), Medical Society for the Study of Venereal Disease (MSSVD). 2002 national guideline on the management of molluscum contagiosum. London: Association for Genitourinary Medicine (AGUM), Medical Society for the Study of Venereal Disease (MSSVD); 2002. Various p.

## COMPLETE SUMMARY CONTENT

SCOPE  
METHODOLOGY - including Rating Scheme and Cost Analysis  
RECOMMENDATIONS  
EVIDENCE SUPPORTING THE RECOMMENDATIONS  
BENEFITS/HARMS OF IMPLEMENTING THE GUIDELINE RECOMMENDATIONS  
CONTRAINDICATIONS  
QUALIFYING STATEMENTS  
IMPLEMENTATION OF THE GUIDELINE  
INSTITUTE OF MEDICINE (IOM) NATIONAL HEALTHCARE QUALITY REPORT  
CATEGORIES  
IDENTIFYING INFORMATION AND AVAILABILITY  
DISCLAIMER

## SCOPE

### DISEASE/CONDITION(S)

- Genital molluscum contagiosum
- Human immunodeficiency virus (HIV) infection

### GUIDELINE CATEGORY

Diagnosis  
Evaluation  
Management  
Treatment

## **CLINICAL SPECIALTY**

Dermatology  
Family Practice  
Infectious Diseases  
Internal Medicine  
Obstetrics and Gynecology  
Urology

## **INTENDED USERS**

Advanced Practice Nurses  
Nurses  
Physician Assistants  
Physicians  
Public Health Departments

## **GUIDELINE OBJECTIVE(S)**

- To enable the healthcare practitioner to reassure a patient with genital molluscum contagiosum (MC) that their condition is harmless and to offer an appropriate plan of management
- To highlight key clinical features that should allow the diagnosis of genital MC to be made with confidence and to outline the treatment options

## **TARGET POPULATION**

Patients in the United Kingdom with molluscum contagiosum

**Note:** This guideline is aimed primarily at people aged 16 or older presenting to health care professionals working in departments offering level 3 care in sexually transmitted infection (STI) management in England and Wales, tier 5 in Scotland. However, the recommendations are appropriate in all health care settings.

## **INTERVENTIONS AND PRACTICES CONSIDERED**

### **Evaluation/Diagnosis**

1. Assessment of clinical features, including signs, symptoms, and evidence of secondary infection
2. Examination of the core of lesions by electron microscopy

### **Management/Treatment**

1. General advice
2. A full screen for sexually transmitted infections

3. Human immunodeficiency virus (HIV) testing in patients presenting with facial lesions
4. Cryotherapy
5. Expression of the pearly core, either manually or using forceps
6. Piercing with an orange stick, with or without the application of tincture of iodine, or phenol
7. Curettage or diathermy under local anaesthesia
8. Podophyllotoxin cream (0.5%)
9. Imiquimod 5% cream for use in men
10. In patients with HIV infection, the introduction of highly active antiretroviral therapy
11. Considerations for pregnant and breastfeeding women
12. Follow-up

**Note:** There are no medicines licensed for the treatment of molluscum contagiosum (MC) in the United Kingdom.

## **MAJOR OUTCOMES CONSIDERED**

Safety and efficacy of treatment

## **METHODOLOGY**

### **METHODS USED TO COLLECT/SELECT EVIDENCE**

Searches of Electronic Databases

### **DESCRIPTION OF METHODS USED TO COLLECT/SELECT THE EVIDENCE**

A Medline search was undertaken using search terms molluscum contagiosum, genital and randomised controlled trial (RCT). The Cochrane database was also searched under molluscum contagiosum (MC). Trials restricted to children aged <16 years only were excluded. One systemic review of treatment of MC in the Cochrane database was also excluded as it did not consider the treatment of sexually transmitted MC. Two studies involving the use of podophyllotoxin and imiquimod were considered. The study on imiquimod used a 1% cream whereas the 5% preparation is available in the United Kingdom (UK).

### **NUMBER OF SOURCE DOCUMENTS**

Not stated

### **METHODS USED TO ASSESS THE QUALITY AND STRENGTH OF THE EVIDENCE**

Weighting According to a Rating Scheme (Scheme Given)

### **RATING SCHEME FOR THE STRENGTH OF THE EVIDENCE**

#### **Levels of Evidence**

**Ia:** Evidence obtained from meta-analysis of randomised controlled trials

**Ib:** Evidence obtained from at least one randomised controlled trial

**IIa:** Evidence obtained from at least one well designed controlled study without randomisation

**IIb:** Evidence obtained from at least one other type of well designed quasi-experimental study

**III:** Evidence obtained from well designed non-experimental descriptive studies such as comparative studies, correlation studies, and case control studies

**IV:** Evidence obtained from expert committee reports or opinions and/or clinical experience of respected authorities

## **METHODS USED TO ANALYZE THE EVIDENCE**

Systematic Review

## **DESCRIPTION OF THE METHODS USED TO ANALYZE THE EVIDENCE**

Not stated

## **METHODS USED TO FORMULATE THE RECOMMENDATIONS**

Expert Consensus

## **DESCRIPTION OF METHODS USED TO FORMULATE THE RECOMMENDATIONS**

Not stated

## **RATING SCHEME FOR THE STRENGTH OF THE RECOMMENDATIONS**

### **Grading of Recommendations**

#### **A (Evidence Levels Ia, Ib)**

- Requires at least one randomised controlled trial as part of the body of literature of overall good quality and consistency addressing the specific recommendation.

#### **B (Evidence Levels IIa, IIb, III)**

- Requires availability of well conducted clinical studies but no randomised clinical trials on the topic of recommendation.

#### **C (Evidence Level IV)**

- Requires evidence from expert committee reports or opinions and/or clinical experience of respected authorities. Indicates absence of directly applicable studies of good quality.

## **COST ANALYSIS**

A formal cost analysis was not performed and published cost analyses were not reviewed.

## **METHOD OF GUIDELINE VALIDATION**

External Peer Review  
Internal Peer Review

## **DESCRIPTION OF METHOD OF GUIDELINE VALIDATION**

Successive drafts of the guideline have been reviewed by the Clinical Effectiveness Group (CEG) of the British Association for Sexual Health and HIV (BASHH). The guideline was posted for comment for 3 months on the BASHH website.

# **RECOMMENDATIONS**

## **MAJOR RECOMMENDATIONS**

Definitions of the levels of evidence **(I-IV)** and grades of recommendation **(A-C)** are defined at the end of the "Major Recommendations" field.

### **Diagnosis**

- This is usually based on characteristic clinical appearance.
- The main differential diagnosis is with genital warts, which are neither smooth nor umbilicated.
- The core of lesions can be examined by electron microscopy, under which typical poxvirus-like particles will be seen.

### **Management**

#### **General Advice**

As the natural history is of spontaneous regression of lesions, treatment is offered for cosmetic reasons only.

#### **Further Investigation**

- As other sexually transmitted infections (STIs) may co-exist; a full screen for these should be undertaken (**Level of evidence III, Grade of recommendation B**).
- Human immunodeficiency virus (HIV) testing is recommended in patients presenting with facial lesions (**Level of evidence III, Grade of recommendation B**).

## Treatment

The aim is tissue destruction, with viral demise accompanying this. There are no medicines licensed for the treatment of molluscum contagiosum (MC) in the United Kingdom (UK).

## Recommended Regimens

- Cryotherapy – apply liquid nitrogen until a halo of ice surrounds the lesion. Repeat applications may be necessary (**Level of evidence IV, Grade of recommendation C**).
- Expression of the pearly core, either manually or using forceps (**Level of evidence IV, Grade of recommendation C**).
- Piercing with an orange stick, with or without the application of tincture of iodine or phenol (**Level of evidence IV, Grade of recommendation C**).
- Curettage or diathermy may be carried out under local anaesthesia (**Level of evidence IV, Grade of recommendation C**).
- Podophyllotoxin cream (0.5%) can be self-applied in men (**Level of evidence Ib, Grade of recommendation A**).
- Imiquimod 5% cream can be self-applied in men (**Level of evidence Ib, Grade of recommendation A**).
- In patients with HIV infection, the introduction of highly active antiretroviral therapy may lead to the resolution of lesions (**Level of evidence III, Grade of recommendation B**).

## Allergy

- Treatments to which there is known hypersensitivity should be avoided

## Pregnancy and Breastfeeding

- Cryotherapy and other, purely destructive methods are safe.
- Podophyllotoxin is contraindicated. The British National Formulary advises that Imiquimod should be used with caution.

## Sexual Partners

- Contact tracing of partners is unnecessary

## Definitions:

### Levels of Evidence

**Ia:** Evidence obtained from meta-analysis of randomised controlled trials

**Ib:** Evidence obtained from at least one randomised controlled trial

**IIa:** Evidence obtained from at least one well designed controlled study without randomisation

**IIb:** Evidence obtained from at least one other type of well designed quasi-experimental study

**III:** Evidence obtained from well designed non-experimental descriptive studies such as comparative studies, correlation studies, and case control studies

**IV:** Evidence obtained from expert committee reports or opinions and/or clinical experience of respected authorities

### **Grading of Recommendations**

#### **A (Evidence levels Ia, Ib)**

- Requires at least one randomised controlled trial as part of the body of literature of overall good quality and consistency addressing the specific recommendation.

#### **B (Evidence levels IIa, IIb, III)**

- Requires availability of well conducted clinical studies but no randomised clinical trials on the topic of recommendation.

#### **C (Evidence level IV)**

- Requires evidence from expert committee reports or opinions and/or clinical experience of respected authorities. Indicates absence of directly applicable studies of good quality.

### **CLINICAL ALGORITHM(S)**

None provided

## **EVIDENCE SUPPORTING THE RECOMMENDATIONS**

### **TYPE OF EVIDENCE SUPPORTING THE RECOMMENDATIONS**

The type of supporting evidence is identified and graded for selected recommendations (see "Major Recommendations").

## **BENEFITS/HARMS OF IMPLEMENTING THE GUIDELINE RECOMMENDATIONS**

### **POTENTIAL BENEFITS**

Appropriate diagnosis, treatment and management of patients with molluscum contagiosum

### **POTENTIAL HARMS**

Not stated

## CONTRAINDICATIONS

### CONTRAINDICATIONS

- Treatments to which there is known hypersensitivity should be avoided.
- Podophyllotoxin is contraindicated in women who are pregnant or breastfeeding.
- The British National Formulary advises that imiquimod should be used with caution in women who are pregnant or breastfeeding.

## QUALIFYING STATEMENTS

### QUALIFYING STATEMENTS

- The study on imiquimod that guideline developers considered used a 1% cream whereas the 5% preparation is available in the United Kingdom.
- The recommendations in this guideline may not be appropriate for use in all clinical situations. Decisions to follow these recommendations must be based on the professional judgement of the clinician and consideration of individual patient circumstances.
- All possible care has been undertaken to ensure the publication of the correct dosage of medication and route of administration. However, it remains the responsibility of the prescribing physician to ensure the accuracy and appropriateness of the medication they prescribe.

## IMPLEMENTATION OF THE GUIDELINE

### DESCRIPTION OF IMPLEMENTATION STRATEGY

An implementation strategy was not provided.

### IMPLEMENTATION TOOLS

Audit Criteria/Indicators

For information about [availability](#), see the "Availability of Companion Documents" and "Patient Resources" fields below.

## INSTITUTE OF MEDICINE (IOM) NATIONAL HEALTHCARE QUALITY REPORT CATEGORIES

### IOM CARE NEED

Getting Better

### IOM DOMAIN

Effectiveness



## IDENTIFYING INFORMATION AND AVAILABILITY

### **BIBLIOGRAPHIC SOURCE(S)**

Clinical Effectiveness Group, British Association for Sexual Health and HIV (BASHH). United Kingdom national guideline on the management of molluscum contagiosum. London (UK): British Association for Sexual Health and HIV (BASHH); 2008 Feb 15. 5 p. [11 references]

### **ADAPTATION**

Not applicable: The guideline was not adapted from another source.

### **DATE RELEASED**

1999 Aug (revised 2008 Feb 15)

### **GUIDELINE DEVELOPER(S)**

British Association for Sexual Health and HIV - Medical Specialty Society

### **SOURCE(S) OF FUNDING**

Not stated

### **GUIDELINE COMMITTEE**

Clinical Effectiveness Group (CEG)

### **COMPOSITION OF GROUP THAT AUTHORED THE GUIDELINE**

*Author:* Gordon Scott, Lauriston Building, Edinburgh

*Clinical Effectiveness Group (CEG) Members:* Dr Keith Radcliffe, Whittal Street Clinic, Birmingham (BASHH); Dr Imtyaz Ahmed-Jusuf, Nottingham City Hospital (BASHH); Dr David Daniels, West Middlesex Hospital (Chair NAG); Dr Mark FitzGerald, Taunton and Somerset (BASHH); Dr Neil Lazaro (RCGP); Dr Guy Rooney, Swindon and Oxford (RCP); Dr Gill McCarthy, Kingston Hospital (BASHH)

### **FINANCIAL DISCLOSURES/CONFLICTS OF INTEREST**

Conflict of Interest: None

This guideline was commissioned and edited by the Clinical Effectiveness Group (CEG) of the British Association for Sexual Health and HIV (BASHH), without external funding being sought or obtained.

### **GUIDELINE STATUS**

This is the current release of the guideline.

This guideline updates a previous version: Association for Genitourinary Medicine (AGUM), Medical Society for the Study of Venereal Disease (MSSVD). 2002 national guideline on the management of molluscum contagiosum. London: Association for Genitourinary Medicine (AGUM), Medical Society for the Study of Venereal Disease (MSSVD); 2002. Various p.

## **GUIDELINE AVAILABILITY**

Electronic copies: Available from the [British Association for Sexual Health and HIV Web site](#).

## **AVAILABILITY OF COMPANION DOCUMENTS**

The following is available:

- Specifications for the development of UK guidelines on the management of sexually transmitted infections (STIs) and closely related conditions 2005. London (UK): British Association for Sexual Health and HIV (BASHH); 2005. 14 p. Electronic copies: Available in Portable Document Format (PDF) from the [British Association for Sexual Health and HIV Web site](#).

Additionally, auditable outcome measures can be found in the [original guideline document](#).

## **PATIENT RESOURCES**

None available

## **NGC STATUS**

This summary was completed by ECRI on December 8, 2000. The information was verified by the guideline developer on January 12, 2001. This summary was updated on August 5, 2002. This summary was updated by ECRI Institute on June 24, 2008. The updated information was verified by the guideline developer on June 30, 2008.

## **COPYRIGHT STATEMENT**

This NGC summary is based on the original guideline, which is subject to the guideline developers and/or BMJ Publishing Group's copyright restrictions. Reproduction and use of this guideline is permitted provided that (a) the original content is not changed or edited; and, (b) any content derived from the original guideline is acknowledged as that of the author(s) and responsible organizations.

Readers wishing to download and reproduce material for purposes other than personal study or education should contact BMJPG to seek permission first. Contact: BMJ Publishing Group, BMA House, Tavistock Square, WC1H 9JR, UK.

## DISCLAIMER

### NGC DISCLAIMER

The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.

All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.

Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at <http://www.guideline.gov/about/inclusion.aspx>.

NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding guideline content are directed to contact the guideline developer.

© 1998-2008 National Guideline Clearinghouse

Date Modified: 11/3/2008

